Is long-term follow-up solely by imaging tests safe in non-operated pancreatic neuroendocrine tumors?

Rev Esp Enferm Dig. 2024 Apr;116(4):209-215. doi: 10.17235/reed.2023.9293/2022.

Abstract

Introduction: the diagnosis of asymptomatic sporadic nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) has increased significantly due to the widespread use of high-resolution imaging tests, which is why the most appropriate management at the time of diagnosis is the subject of debate, as is how to follow-up patients.

Aims: the objective of this study was to analyze the frequency of imaging and endoscopic studies performed during long-term follow-up.

Methods: a retrospective review was performed of a database collected between January 2008 and December 2020 of patients with an incidental diagnosis of small NF-PNETs; follow-up was closed in March 2023. The imaging tests performed at the time of diagnosis and long-term follow-up were recorded. Growing less than 1 mm per year has not been considered as a worrisome feature. Follow-up was performed through imaging tests, considering endoscopic cytology for lesions with a faster grow rate.

Results: fifty-eight patients were included; the median age was 69 years. The initial mean size of the lesions studied was 12.79 mm (5-27). Follow-up was carried out only with computed tomography (CT) or magnetic resonance imaging (MRI). The initial size did not influence the behavior of the lesion in a statistically significant manner. Twenty-eight tumors (45 %) increased in size, with a growth equal to or less than 4 mm in 24 cases. The mean follow-up time was 82.41 months (12-164). No patient developed metastasis or died from PNET progression.

Conclusions: the follow-up of neuroendocrine tumors of small size can be performed safely with only imaging tests.

MeSH terms

  • Aged
  • Follow-Up Studies
  • Humans
  • Neuroectodermal Tumors, Primitive*
  • Neuroendocrine Tumors* / surgery
  • Pancreatic Neoplasms* / pathology
  • Retrospective Studies